Lurasidone-induced tardive dyskinesia
Shreyas Shrikant Pendharkar, Shilpa Avinash Telgote
Annals of Indian Psychiatry · 2022
doi:10.4103/aip.aip_91_20 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Lurasidone is a novel atypical antipsychotic with additional antidepressant and pro-cognitive properties. The drug has shown good efficacy in treatment of schizophrenia as well as bipolar disorder. It is currently used as monotherapy as well as adjunctive therapy with Lithium or valproate, due to its lower propensity of cardiometabolic side effects and endocrinological adverse effects. Extra pyramidal side effects and akathisia with lurasidone therapy are reported in a minority of patients, but very few instances of tardive dyskinesia with lurasidone therapy are reported so far.
Abstract licence: CC BY-NC-SA
References6
6 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.